Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06788171 |
TitlePULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM | 阶段
第二阶段
|
Date Added 2025-03-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT03650348 |
TitlePRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | 阶段
第 1 阶段
|
Date Added 2018-08-28 |
地点
California, United States
Louisiana, United States New York, United States Ohio, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
PRS-343 in Combination with Atezolizumab, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT01697371 |
Title质子疗法在肝转移瘤治疗中的应用 | 阶段
不适用
|
Date Added 2012-10-02 |
地点
California, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06120127 |
TitlePostoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence | 阶段
第二阶段
|
Date Added 2023-11-07 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Chemotherapy, PD-1 antibody |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04117087 |
TitlePooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer | 阶段
第 1 阶段
|
Date Added 2019-10-07 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ipilimumab, Nivolumab, Opdivo, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT06300463 |
Title结直肠癌肝转移免疫疗法组合平台研究 | 阶段
第二阶段
|
Date Added 2024-03-08 |
地点
New York, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
AGEN1423, Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT03868228 |
Title用于治疗结直肠腹膜转移瘤的 PIPAC | 阶段
第 1 阶段
|
Date Added 2019-03-11 |
地点
英国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04708470 |
TitlePhase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2021-01-14 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bintrafusp alfa, Entinostat, NHS-IL12 |
标签
MSS/ MMRp
|
| NCT ID NCT06149481 |
Title联合免疫疗法方案的 I/II 期研究：治疗转移性结直肠癌 (mCRC) 的联合免疫疗法方案：SX-682、TriAdeno 疫苗、雷替凡利单抗和 IL-15 激动剂 N-803 (STAR15) | 阶段
Phase 1, Phase 2
|
Date Added 2023-11-29 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
N-803, Retifanlimab, SX-682 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02484404 |
Title抗程序性死亡配体-1 Durvalumab抗体（MEDI4736）与奥拉帕利（Olaparib）和/或塞地拉尼（Cediranib）联合治疗晚期实体瘤和晚期或复发性卵巢癌、三阴性乳腺癌、肺癌、前列腺癌和结直肠癌的I/II期研究... | 阶段
Phase 1, Phase 2
|
Date Added 2015-06-29 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cediranib, durvalumab, Olaparib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
